Expression of pERK and VEGFR‐2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|8|2001-2008

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.8, 2015-08, pp. : 2001-2008

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite

Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 91, Iss. 5, 2016-09 ,pp. : 261-266

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 84, Iss. 1, 2012-10 ,pp. : 6-13

Karger

Access to resources Recommend Favorite

Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada

By Muszbek Noemi   Shah Sonalee   Carroll Stuart   McDonald Heather   Dale Peter   Maroun Jean   Knox Jennifer  

Current Medical Research and Opinion, Vol. 24, Iss. 12, 2008-12 ,pp. : 3559-3569

Informa Healthcare

Access to resources Recommend Favorite